HER2 Breast Cancer

This segment takes a deeper dive into toxicity management—focusing not just on what to monitor, but how institutions are putting these protocols into action in real-world clinical settings.

Trastuzumab deruxtecan (T-DXd) yielded favorable outcomes and improved survival rates.

The data were presented at the ESMO Breast Cancer 2025 Annual Meeting.

Studies suggest that prolonged activation of MUC1-C encourages disease progression.

Pharmacists compare real-world practice data with clinical trial results and discuss supportive care options for patients.

New data reveals that combining pertuzumab with trastuzumab significantly improves survival rates in HER2+ breast cancer patients, reducing death risk by 17%.

Explore the latest insights on emerging antibody drug conjugates for HER2 breast cancer and real-world management strategies.

Trastuzumab deruxtecan was safe and efficacious prior to treatment with paclitaxel, trastuzumab, and pertuzumab.

This installment of our series on ADCs and HER2 breast cancer offers key insights about novel agents in clinical trials and management of ADC therapies.

Pharmacists discuss how drug design impacts drug efficacy and indications for HER2-low and -ultra-low breast cancer.

Pyrotinib is a tyrosine kinase inhibitor that is independently developed in China.

Patients in both arms achieved statistically significant rates of compliance up to 97%.

PAK5 is a protein that drives resistance to trastuzumab emtansine in patients with HER2+ breast cancer.

The meaningful results were reported in the DESTINY-Breast09 trial.

Sequencing of antibody-drug conjugates (ADCs) in HER2-mutated breast cancer is crucial for optimizing treatment outcomes.

Antibody-drug conjugates have revolutionized metastatic breast cancer treatment and classification.

The data showed improvements in overall response rates, progression-free survival, and duration of response.

Imlunestrant is an investigational, brain-penetrating, oral selective degrader of estrogen receptor.

Julia Ziegengeist, PharmD, BCOP offers insights for pharmacists navigating adjuvant and neoadjuvant treatment of breast cancer.

The predictive tool may reveal the mechanisms underlying treatment resistance in patients with HER+ breast cancer.

The findings extend prior data underscoring the clinical benefit of the agent and its place in global clinical practice guidelines.

Vepdegestrant is an experimental oral PROteolysis TArgeting Chimera that degrades estrogen receptor (ER) in patients with metastatic breast cancer.

Camizestrant is an investigational oral selective estrogen receptor degrader.

Patients achieved an overall survival of 12.4 months.

Tanshinlactone is an active ingredient that is commonly used in Chinese herbal medicine.